PH
Prism Health North Texas at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Prism Health North Texas brings 3 presentations to IDWeek 2026 in Washington. Its program centres on how people living with HIV experience newer treatment options, measured through patient-reported outcomes. It compares daily doravirine/islatravir with a bictegravir-based regimen in people starting therapy, and follows suppressed adults who switch to weekly oral islatravir with ulonivirine.
| Organization | IDWeek 2026 Attendance |
|---|---|
PH Prism Health North Texas Dallas, TX | |
Poster Fri Oct 23 12:15pm–1:30pm Patient-Reported Outcomes With Doravirine/Islatravir (100/0.25 mg) Once Daily Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Previously Untreated Adults Living With HIV-1: Phase 3 Week 48 Results Poster Fri Oct 23 12:15pm–1:30pm Patient-Reported Outcomes With Doravirine/Islatravir (100/0.25 mg) Once Daily Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Previously Untreated Adults Living With HIV-1: Phase 3 Week 48 Results Talk Fri Oct 23 2:09pm–2:21pm Patient-Reported Outcomes From Virologically Suppressed Adults Living With HIV-1 Switching to Once-Weekly Oral Islatravir in Combination With Ulonivirine: Phase 2b Week 24 Results HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship |
Instantly find 20 buyers from Prism Health North Texas
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction